Hypoalphalipoproteinemia

From Citizendium
Revision as of 14:45, 31 January 2013 by imported>Robert Badgett
Jump to navigation Jump to search
This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Hypoalphalipoproteinemias, also called familial high density lipoprotein deficiency disease and HDL lipoprotein deficiency disease, are defined as "conditions with abnormally low levels of alpha-lipoproteins (high-density lipoproteins) in the blood. Hypoalphalipoproteinemia can be associated with mutations in genes encoding apolipoprotein A-I; lecithin cholesterol acyltransferase; and ATP-binding cassette transporters."[1] This causes hypertriglyceridemia.

Treatment

Using gemfibrozil to treat hypoalphalipoproteinemia may reduce major cardiovascular events[2] and stroke[3] and in men with known men with known coronary heart disease.

Using simvastatin plus niacin to treat hypoalphalipoproteinemia may reduce cardiovascular event in men with coronary heart disease.[4]

References

  1. Anonymous (2024), Hypoalphalipoproteinemia (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Rubins HB, Robins SJ, Collins D, et al (1999). "Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group". N. Engl. J. Med. 341 (6): 410–8. PMID 10438259[e]
  3. Bloomfield Rubins H, Davenport J, Babikian V, et al (2001). "Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT)". Circulation 103 (23): 2828–33. PMID 11401940[e]
  4. Brown BG, Zhao XQ, Chait A, et al (2001). "Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease". N. Engl. J. Med. 345 (22): 1583–92. PMID 11757504[e]